Craig Millian Net Worth

The estimated Net Worth of Craig Stuart Millian is at least $1.42 Million dollars as of 10 August 2022. Mr. Millian owns over 5,000 units of Corbus Pharmaceuticals Inc stock worth over $1,423,170 and over the last 6 years he sold CRBP stock worth over $0. In addition, he makes $0 as Chief Commercial Officer at Corbus Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Millian CRBP stock SEC Form 4 insiders trading

Craig has made over 8 trades of the Corbus Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CRBP stock worth $1,250 on 10 August 2022.

The largest trade he's ever made was buying 10,000 units of Corbus Pharmaceuticals Inc stock on 10 March 2022 worth over $3,700. On average, Craig trades about 2,077 units every 96 days since 2019. As of 10 August 2022 he still owns at least 27,000 units of Corbus Pharmaceuticals Inc stock.

You can see the complete history of Mr. Millian stock trades at the bottom of the page.

Craig Millian biography

Craig Stuart Millian serves as Chief Commercial Officer of the Company. Mr. Millian brings 25 years of experience leading commercial organizations for a range of pharmaceutical companies during all stages of development and commercialization. Prior to joining Corbus, Mr. Millian held various leadership positions at EMD Serono, Inc., including Senior Vice President, Head of U.S. Fertility and Endocrinology from 2012 to 2016, and Senior Vice President, Head of U.S. Neurology and Immunology from 2016 to 2018. In these roles, he was responsible for leading the strategic direction and driving operating results for these franchises in the U.S. He oversaw areas of the business including sales, marketing and patient support services. Previously, Mr. Millian served as Vice President, Commercial at Vertex Pharmaceuticals Inc. (“Vertex”), where he helped design and build the commercial infrastructure, organizational capabilities and go-to-market plans in advance of launching the Vertex product pipeline. Prior to Vertex, he held commercial leadership roles at Pfizer Inc. and Sanofi. Mr. Millian holds an MBA from New York University and a degree in Finance from the University of Pennsylvania.

How old is Craig Millian?

Craig Millian is 52, he's been the Chief Commercial Officer of Corbus Pharmaceuticals Inc since 2019. There are 9 older and 2 younger executives at Corbus Pharmaceuticals Inc. The oldest executive at Corbus Pharmaceuticals Holdings Inc is Avery Catlin, 72, who is the Independent Director.

What's Craig Millian's mailing address?

Craig's mailing address filed with the SEC is 500, River Ridge Drive, Norwood, Norfolk County, Massachusetts, 02062, United States.

Insiders trading at Corbus Pharmaceuticals Inc

Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor... und Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.

What does Corbus Pharmaceuticals Inc do?

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.

Complete history of Mr. Millian stock trades at Corbus Pharmaceuticals Inc

Corbus Pharmaceuticals Inc executives and stock owners

Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Yuval Cohen,
  Chief Executive Officer, Director
• Barbara White,
  Chief Medical Officer 
• Sean Moran,
  Chief Financial Officer
• Dr. Yuval Cohen,
  CEO & Director
• Rachelle Jacques,
  Independent Director
• Sean F. Moran CPA, M.B.A., CPA, MBA,
  Chief Financial Officer
• Alan Holmer,
  Independent Chairman of the Board
• Avery Catlin,
  Independent Director
• John Jenkins,
  Independent Director
• Ted Jenkins,
  Senior Director, Investor Relations and Communications
• Peter Salzmann,
  Independent Director
• Craig Millian,
  Chief Commercial Officer
• Scott Constantine,
  Sr. Director & Head of Clinical Operations
• Christina Bertsch,
  Head of HR
• Lindsey Smith,
  Head of Corp. Communications & Patient Advocacy
• Dr. Rachael Brake Ph.D.,
  Chief Scientific Officer
• Craig Stuart Millian M.B.A.,
  Chief Operating Officer.
• David P Hochman,
  Director
• Mark Tepper,
  President and CSO
• Renu Gupta,
  Director
• George Golumbeski,
  Director
• Asset Management, Lp Cormor...,
  
• Anne Altmeyer,
  
• Yong Ben,
  
• Paris Panayiotopoulos,
  Director
• Asset Management, Lp Chen B...,
  
• Dominic Smethurst,
  Chief Medical Officer
• Sumner Burstein,
  10% owner
• Robert Paul Discordia,
  Chief Operating Officer
• Rachael Louise Brake,
  Chief Scientific Officer
• Winston Kung,